Clinical trials: Multiple Myeloma
Multiple Myeloma, Exercise
Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant.
- Conditions
- Multiple Myeloma, Exercise, Prehabilitation
- Trial name
- MOTIVATE (NCT06280924)
- Testing
- Supported Exercise, Standard Care
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Multiple Myeloma, Plasma Cell Leukemia
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality.
- Trial name
- UltraFrailMM (NCT06517017)
- Testing
- Isatuximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM)
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
Background: Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatment (relapse) in almost all people; MM may also not respond to initial treatment (refractory).
- Trial name
- NCT06876142
- Testing
- Mirdametinib, Sirolimus
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and…
- Trial name
- NCT06948084
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib
- Where
- 29 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms.
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple Myeloma Refractory
- Trial name
- NCT07634263
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Multiple Myeloma (MM), CART Therapy
Neurocognitive Trajectories After BCMA CAR-T
The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).
- Conditions
- Multiple Myeloma (MM), CART Therapy, Refractory Multiple Myeloma (RRMM)
- Trial name
- CAR-T Cog (NCT07740317)
- Testing
- Standardized neurocognitive testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Myeloma Multiple
RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab
Elranatamab is an effective BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma (RRMM). However, implementation in routine practice remains challenging due to monitoring requirements during step-up dosing…
- Trial name
- RE-RITE (NCT07891871)
- Volunteers
- 400 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously) with VRd (Bortezomib, Lenalidomide, and Dexamethasone)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Solid Tumours, Multiple Myeloma
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
This study is a multi-centre, investigator-initiated, Phase I clinical trial evaluating different dosing schedules of VS-6766, given either alone or in combination with everolimus, in patients with advanced solid tumours or…
- Conditions
- Solid Tumours, Multiple Myeloma, Lung Cancer, Ovarian Cancer
- Trial name
- RAF/MEK (NCT02407509)
- Testing
- VS-6766, Everolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 104 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Lyphoma, B-Cell, Leukemia, B-cell
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Background: Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects.
- Conditions
- Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT02473757
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed and/or Refractory Multiple Myeloma
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with…
- Trial name
- NCT03715478
- Testing
- GSK2857916 with Pomalidomide and Dexamethasone
- Where
- 9 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Myeloma Research Group
Multiple Myeloma
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a…
- Trial name
- NCT04786028
- Testing
- Isatuximab
- Where
- 7 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Canadian Myeloma Research Group
Multiple Myeloma, Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36…
- Conditions
- Multiple Myeloma, Myeloma, Myeloma Multiple
- Trial name
- NCT05651932
- Testing
- Cohort A1 & A2: KTX-1001, Cohort B1 & B2: KTX-1001+Mezigdomide, Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)
- Where
- 29 sites in United States, Canada and 2 more
- Volunteers
- 165 people
- Sponsor
- K36 Therapeutics, Inc.
B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma
Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to standard of care (SOC) in…
- Trial name
- NCT06052826
- Testing
- Best Practice, Cognitive Intervention, Comprehensive Geriatric Assessment
- Where
- 4 sites in United States
- Volunteers
- 164 people
- Sponsor
- City of Hope Medical Center
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to…
- Trial name
- NCT06465316
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 16 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult…
- Trial name
- NCT06953960
- Testing
- Surzetoclax, Daratumumab, Dexamethasone
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 325 people
- Sponsor
- AbbVie